相关实验视频
Updated: Jun 29, 2025

08:44
Assembly and Characterization of Polyelectrolyte Complex Micelles
Published on: March 2, 2020
10.7K
多电解质-蛋白质协同作用:pH响应的多电解质/胰岛素复合物作为向蛋白质和药物输送的多功能载体
Anastasiia Murmiliuk1, Hiroki Iwase2, Jia-Jhen Kang1
1Jülich Centre for Neutron Science (JCNS) at Heinz Maier-Leibnitz Zentrum (MLZ), Forschungszentrum Jülich GmbH, Lichtenbergstraße 1, 85747 Garching, Germany.
Journal of colloid and interface science
|March 31, 2024
概括
研究人员探索了蛋白质/多电解质 (PE) 复合物用于药物输送. 他们发现,控制pH和离子强度会影响纳米粒子结构,并使充电药物的封装成为可能,为先进的纳米载体铺平了道路.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 聚合物化学 聚合物化学
背景情况:
- 蛋白质/多电解质 (PE) 联合组装为药物输送提供可调节的纳米载体设计.
- 蛋白质的结构复杂性阻碍了对纳米粒子属性的预测.
- 确定蛋白质/PE复合体中形态转换的触发因素对于有针对性的传递至关重要.
研究的目的:
- 确定蛋白质/PE复合体中形态转变的关键触发因素.
- 评估这些复合物的药物封装和释放能力.
- 开发用于组合疗法的新型纳米载体.
主要方法:
- 使用的双块共聚合物具有聚化和中性水友性块.
- 研究了与胰岛素在5-8的pH范围内的联合组装.
- 使用微角中子和X射线散射 (SANS,SAXS) 来分析结构.
- 使用光来观察药物封装和释放.
主要成果:
- 已证明特定PE共聚物与胰岛素的可逆共组合.
- 表明胰岛素的排列是由静电力和离子强度控制的.
- 对负电荷双价药物的封装和受控释放的观察潜力.
- 开发了具有可调节电荷,稳定性和大小的蛋白质/PE复合体.
结论:
- 蛋白质/PE复合体可以被设计为可控制的药物输送.
- 形态转变是由pH值和离子强度触发的.
- 这些纳米载体显示出对具有可调节性质的组合疗法的前景.
更多相关视频
相关概念视频
Protein-protein Interfaces
12.5K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K
Insulin: Biosynthesis, Chemistry, and Preparation
374
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
374
Pore Transport and Ion-Pair Transport
437
Pore transport and ion-pair formation are critical mechanisms for the absorption and distribution of drugs in the body.
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct...
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct...
437
Insulin Formulations: Types and Delivery
193
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
193
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Insulin Secretory Vesicles
4.9K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.9K

